These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11012021)

  • 21. A QSAR study on a series of pyrrole derivatives acting as lymphocyte-specific kinase (Lck) inhibitors.
    Anwer Z; Gupta SP
    Med Chem; 2012 Jul; 8(4):649-55. PubMed ID: 22548340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
    Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.
    Oguro Y; Miyamoto N; Takagi T; Okada K; Awazu Y; Miki H; Hori A; Kamiyama K; Imamura S
    Bioorg Med Chem; 2010 Oct; 18(20):7150-63. PubMed ID: 20833551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
    J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of echiguanine analogs and their ribofuranosyl glycosides that inhibit phosphatidylinositol 4-kinase.
    Saito Y; Kato K; Umezawa K
    Nucleic Acids Symp Ser; 1997; (37):13-4. PubMed ID: 9585975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
    Burchat A; Borhani DW; Calderwood DJ; Hirst GC; Li B; Stachlewitz RF
    Bioorg Med Chem Lett; 2006 Jan; 16(1):118-22. PubMed ID: 16216497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
    Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disubstituted pyrimidines as Lck inhibitors.
    Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
    Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
    Xing R; Zhang H; Yuan J; Zhang K; Li L; Guo H; Zhao L; Zhang C; Li S; Gao T; Liu Y; Wang L
    Eur J Med Chem; 2017 Oct; 139():531-541. PubMed ID: 28830032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117.
    Das J; Lin J; Moquin RV; Shen Z; Spergel SH; Wityak J; Doweyko AM; DeFex HF; Fang Q; Pang S; Pitt S; Shen DR; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2003 Jul; 13(13):2145-9. PubMed ID: 12798323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
    Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
    Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-based design of peptidomimetic antagonists of p56(lck) SH2 domain.
    Hobbs CJ; Bit RA; Cansfield AD; Harris B; Hill CH; Hilyard KL; Kilford IR; Kitas E; Kroehn A; Lovell P; Pole D; Rugman P; Sherborne BS; Smith IE; Vesey DR; Walmsley DL; Whittaker D; Williams G; Wilson F; Banner D; Surgenor A; Borkakoti N
    Bioorg Med Chem Lett; 2002 May; 12(10):1365-9. PubMed ID: 11992778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of nonreceptor protein tyrosine kinases during phospholipase C-gamma 1-related uterine contractions in the rat.
    Phillippe M; Sweet LM; Bradley DF; Engle D
    Reprod Sci; 2009 Mar; 16(3):265-73. PubMed ID: 19208792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
    Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2.
    Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Che J; Lee CC; Caldwell J; Kanazawa T; Umemura I; Matsuura N; Ohmori O; Honda T; Gray N; He Y
    Bioorg Med Chem Lett; 2006 May; 16(10):2689-92. PubMed ID: 16524731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1.
    Choi HS; Wang Z; Richmond W; He X; Yang K; Jiang T; Sim T; Karanewsky D; Gu XJ; Zhou V; Liu Y; Ohmori O; Caldwell J; Gray N; He Y
    Bioorg Med Chem Lett; 2006 Apr; 16(8):2173-6. PubMed ID: 16458503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.
    Caldwell JJ; Davies TG; Donald A; McHardy T; Rowlands MG; Aherne GW; Hunter LK; Taylor K; Ruddle R; Raynaud FI; Verdonk M; Workman P; Garrett MD; Collins I
    J Med Chem; 2008 Apr; 51(7):2147-57. PubMed ID: 18345609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.